Kim Kamdar

Dr. Kamdar is a Managing Partner at Domain Associates, a venture capital fund focused on healthcare company creation. Kim has been involved in cutting-edge therapeutic and diagnostics start-ups.

Kim was founding CEO for Truvian Sciences where she remains Chair. Kim was involved with Ariosa Diagnostics until the company was acquired by Roche, Corthera until the company was sold to Novartis and BiPar Sciences until that company was sold to Sanofi. Kim was an early investor and helped to create a number of other companies including Aspen Neuroscience, Syndax Pharmaceuticals (NASDAQ: SNDX) and Adastra. Additional BOD memberships include: Alume Biosciences, EPIC Sciences, Evofem Biosciences (NASDAQ: EVFM), Obalon (NASDAQ: OBLN), Sera Prognostics and Singular Genomics.

Prior to Domain, Kim was a Kauffman Fellow at MPM Capital. She was also a Research Director at Novartis, where she built and led a team focused on the biology, genetics and genomics of model organisms. Kim is the author of ten papers as well as the inventor on seven patents. She received her B.A. from Northwestern University and her Ph.D. in biochemistry and genetics from Emory University.

Kim is currently an Advisory Board Member for Dr. Eric Topol’s NIH supported Clinical and Translational Science Award for Scripps Medicine. Kim also serves as a BOD member for Access Youth Academy, a non-profit helping to transform the lives of underserved youth through academic enrichment, health and wellness, social responsibility and leadership through squash.